Price
No data yet.
Social Signal Score
Analyst Ratings
36 analystsRevenue
$2.82B+170314.96%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Karen Massey
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,863
- Beta
- -0.02
- Country
- NL
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 21.32
Financials
Revenue
$2.82B+170315.0%Net Income
$838.82MEBITDA
$863.85MFree Cash Flow
$748.74M+278591.6%EPS (diluted)
$13.02Shares Outstanding (diluted)
64.41M+310.1%Operating Expenses
$1.26BCash & Debt
$5.18BReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.15B | $1.29B | $21.14 |
| 2024 | $2.19B | $833.04M | $13.92 |
| 2023 | $1.23B | $-295.05M | $-5.16 |
| 2022 | $410.75M | $-709.59M | $-13.05 |
| 2021 | $1.08B | $-408.26M | $-7.99 |
| 2020 | $41.24M | $-608.46M | $-13.40 |
| 2019 | $78.46M | $-181.21M | $-4.69 |
| 2018 | $24.57M | $-76.23M | $-2.12 |
| 2017 | $43.69M | $-33.68M | $-1.37 |
| 2016 | $15.47M | $-22.48M | $-1.19 |
| 2015 | $7.49M | $-16.74M | $-1.06 |
| 2014 | $4.57M | $-12.54M | $-0.80 |
| 2013 | $3.70M | $-8.47M | $-0.54 |
| 2012 | $2.18M | $-12.83M | $-0.82 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $30.97
- Implied price
- $1,239
- Return from $912.87
- 6.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $615.94 — -32.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 28 | 34 | 40 | 46 | 52 |
|---|---|---|---|---|---|
| -2.0% | -10.2% | -6.6% | -3.5% | -0.8% | 1.7% |
| 3.0% | -5.6% | -1.9% | 1.4% | 4.3% | 6.8% |
| 8.0% | -1.0% | 2.9% | 6.3% | 9.3% | 12.0% |
| 13.0% | 3.6% | 7.7% | 11.2% | 14.4% | 17.2% |
| 18.0% | 8.1% | 12.4% | 16.1% | 19.4% | 22.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+600.00%Social Signal Score
Mentions (11)
- Newsfool.com·1d ago·Positive
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now? This biotech stock could soar 30% or more over the next 12 months if some analysts are right.
View source ↗ - Newsglobenewswire.com·7d ago·Positive
…lts in MMN support its potential as a pathway-selective complement therapy September 29, 2026, 8:00 AM EST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, will present new data from across its portfolio and pipeline at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session in Orlando, Florida, from September 29 – October 2…
View source ↗ - Newsfool.com·10d ago·Positive
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months Argenx's Vyvgart franchise enjoys strong sales momentum. The company has multiple registrational data read-outs on the way.
View source ↗ - Newsfool.com·16d ago·Neutral
2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right. Wells Fargo and UBS have 12-month price targets for Argenx that are more than 40% above the current share price. Argenx's momentum and clinical successes appear to justify these lofty expectations.
View source ↗ - Newsseekingalpha.com·21d ago·Positive
argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsfool.com·34d ago·Negative
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? Argenx's top and bottom lines are growing robustly. The company expects to report multiple pivotal clinical results through the second half of 2027.
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
argenx to Present at Upcoming Investor Conferences September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September:
View source ↗ - Newsfool.com·41d ago·Negative
Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story Argenx recently announced Phase 3 results for Vyvgart Hytrulo in treating autoimmune myositis. While there was one disappointment with the clinical study, the results were positive overall.
View source ↗ - Newszacks.com·48d ago·Negative
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.
View source ↗ - Newsseekingalpha.com·49d ago·Positive
argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis Transcript argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis Transcript
View source ↗ - Newsreuters.com·50d ago·Negative
Argenx says efgartigimod met main goal in myositis trial Belgian-Dutch immunology company argenx ARGX.BR said its drug efgartigimod met the primary endpoint in a late-stage study treating adults with autoimmune myositis, showing significant improvement in disease activity.
View source ↗
Earnings
Thu, Mar 4(in 5 months)
Consensus estimate $8.37 per share
Typical surprise +16.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$7.32 vs $6.27beat
- Thu, May 7$5.90 vs $5.16beat
- Thu, Oct 30$5.18 vs $4.37beat
- Thu, May 8$2.58 vs $2.32beat
- Thu, Oct 31$1.39 vs $0.10beat
- Thu, May 9$-1.04 vs $-0.71miss
Estimates and results for ARGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.